

MATTERS ARISING

Open Access



Anticoagulant-related bleeding in patients receiving anticoagulant therapy over 10 years

Lihong Zhu¹ and Juan Lin^{1*}

To the Editor,

In a recent study, Dr. Botrel et al. [1] summarized the characteristics of patients admitted to intensive care units (ICU) for severe anticoagulant-related extracranial bleeding (AREB) in five centers. This study is well designed. However, several limitations should be noted.

First, a total of 95,614 patients admitted to five French ICUs from January 2007 to December 2018 were initially screened. The authors reported that the incidence of AREB increased from 3.2/1000 (18 patients) in 2007 to 5.8/1000 (56 patients) in 2018, which requires medical attention. This result may be incorrectly interpreted.

In this study, the authors used the entire ICU population ($n=95,614$) as the denominator in AREB incidence calculations, which could lead to a biased result. According to the data provided, the total ICU admissions increased from 5625 ($18 \times 1000 / 3.2$) in 2007 to 9655 ($56 \times 1000 / 5.8$) in 2018. However, over the past decade (2007 to 2018), the proportion of patients receiving anticoagulation therapy has also gradually increased. For instance, in China, the percentage of atrial fibrillation patients receiving anticoagulation therapy increased from 2.7% in 2002 [2] to 31.7% in 2012 [3]. Therefore, it is more reasonable to use the number of people receiving anticoagulation therapy as the denominator when calculating the AREB incidence. When the proportion

of patients receiving anticoagulant therapy increases significantly over 10 years, the overall AREB incidence may decrease (for instance, assuming the proportion of patients receiving anticoagulation therapy increased from 15% in 2007 to 60% in 2018 in France, the AREB incidence would decrease from 2.13% ($18 / (5625 \times 15\%)$) to 0.96% ($56 / (9655 \times 60\%)$). This is also consistent with the fact that over time, more people received oral anticoagulants, and dozens of trials [4] have reported that oral anticoagulants have a lower risk of bleeding than traditional anticoagulants such as heparin. Therefore, in theory, the overall probability of bleeding events should not increase.

Second, in the multivariate logistic model, the author kept all variables ($n=17$, including non-significant factors) in the final model and found that only five risk factors remained significant. This may not be appropriate. A logistic regression model [5] could be over-parameterized (i.e., too many variables for too few events) and can result in odds ratio uninterpretable (i.e., 95% CI extremely large or reversed). This may be why some known risk factors (such as age, MV, and RRT) for ICU mortality became non-significant in this model. In addition, the disease severity score (SOFA or SAPS II) should be adjusted to reach a stable result.

Acknowledgements

Not applicable.

Author contributions

LZ raised question and Juan Lin wrote the whole correspondence. All authors reviewed the manuscript.

Funding

None.

Availability of data and materials

Not applicable.

This comment refers to the article available online at <https://doi.org/10.1186/s13054-023-04605-4>.

*Correspondence:

Juan Lin

iculinjjuan1973@163.com

¹ Intensive Care Unit, Zhejiang Hospital, 12# Linyin Road, Hangzhou City 310013, Zhejiang Province, China



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interest.

Received: 11 September 2023 Accepted: 13 September 2023

Published online: 18 September 2023

References

1. Botrel T, Cunat S, Helms J, Lemarie J, Gaillon J, Preau S, Favory R, Thille AW, Boissier F, Maury E, et al. Extracranial anticoagulant related bleedings admitted to intensive care units: a French multicenter retrospective study. *Crit Care*. 2023;27(1):312.
2. Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. *J Am Coll Cardiol*. 2008;52(10):865–8.
3. Sun Y, Zhu J, Ma C, Liu S, Yang Y, Hu D. Stroke risk status, anticoagulation treatment, and quality-of-life in Chinese patients with atrial fibrillation: China Registry of Atrial Fibrillation (CRAF). *Cardiovasc Ther*. 2019;2019:7372129.
4. Hanon O, Vidal JS, Pisica-Donose G, Orvoen G, David JP, Chaussade E, Caillard L, de Jong LW, Bouloche N, Vinsonneau U, et al. Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation. *Heart*. 2021;107(17):1376–82.
5. Zabor EC, Reddy CA, Tendulkar RD, Patil S. Logistic regression in clinical studies. *Int J Radiat Oncol Biol Phys*. 2022;112(2):271–7.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.